Vitamin D (High-Dose Protocol)

The Hormone Reframe: Accurate Biology, Deployed to Move Goalposts

The most influential conceptual move in the vitamin D supplementation community is the reframing of vitamin D as "technically a hormone, not a vitamin." This framing is biologically accurate: the active form of vitamin D (1,25-dihydroxyvitamin D, or calcitriol) is a secosteroid that acts through nuclear receptors to regulate gene transcription — the functional definition of a steroid hormone. Vitamins are substances that must be obtained from diet because the body cannot synthesize them; the body manufactures vitamin D from cholesterol upon UV-B skin exposure, making "vitamin D" a misnomer for what is genuinely a hormone precursor.

In community discourse, however, this accurate observation is deployed to do conceptual work that the biology does not support. The implied argument runs: vitamins have tolerable upper intake limits because you only need a small amount; hormones govern major physiological systems; vitamin D is a hormone; therefore the standard supplementation doses (600–2,000 IU/day) are absurdly conservative and megadoses are not just safe but necessary for hormonal optimization. This reasoning does not follow. Many hormones have narrow therapeutic windows and produce serious pathology at supraphysiologic levels — testosterone, cortisol, thyroid hormone, and vitamin D itself, which causes hypercalcemia at sustained high doses. The hormone classification does not make a substance safe at any dose; it makes the dose-response relationship more important to understand, not less.

The hormone reframe also serves to position mainstream supplement dosing (600–2,000 IU) as coming from a fundamentally incorrect conceptual framework — as if physicians recommending these doses are making the category error of treating a hormone like a vitamin. This creates a rhetorical setup where community members who understand the "hormone" framing feel they possess knowledge mainstream medicine lacks, and are therefore justified in ignoring mainstream dosing guidance. The framing functions well as community identity marker and justification for divergence from clinical guidelines, regardless of whether the pharmacological logic holds up.

r/VitaminD and the Community Consensus Blood Level Targets

The r/VitaminD subreddit has over 100,000 subscribers and functions as the primary English-language community for vitamin D optimization discussions. The community's practical consensus diverges substantially from clinical guidelines on several key questions. Blood level targets: community consensus holds that optimal 25(OH)D is 60–80 ng/mL, sometimes higher; the IOM considers levels above 20 ng/mL adequate, and the Endocrine Society sets sufficiency at 30 ng/mL. The community's target requires supplementation of 5,000–10,000 IU/day or more for most people, since most adults supplementing 2,000 IU/day reach the 40–50 ng/mL range rather than 60–80.

The 60–80 ng/mL target is not based on randomized trial evidence showing that achieving this level produces better outcomes than 30–50 ng/mL. It is derived primarily from observational studies showing that populations or individuals with levels in this range have better health outcomes — subject to the reverse causation critique, which the community does not engage with seriously. The target also draws on an ecological comparison with hunter-gatherer populations studied by researchers like Reinhold Vieth, who argued that humans evolved with much higher sun exposure and therefore higher 25(OH)D than modern indoor populations achieve. This evolutionary baseline argument has some internal logic but cannot establish that supplementing to an ancestral sun-exposure level produces the same health outcomes as actually living with high sun exposure — the D that comes from 6 hours of outdoor physical activity in East Africa arrives alongside cortisol, melatonin regulation, circadian entrainment, and other physiological consequences that a supplement capsule does not replicate.

Testing frequency is another community norm that diverges from clinical practice. Community members test 25(OH)D every 3–6 months, titrating supplements based on results, often without physician involvement. The commercialization of direct-to-consumer blood testing has made this accessible and inexpensive — a 25(OH)D test can be ordered online for $30–50 without a physician order in most US states. The testing-and-titration cycle reinforces engagement with the community and with supplement optimization as a practice, regardless of whether the target levels being optimized toward represent genuine clinical benefit.

The Coimbra Protocol: 40,000–100,000 IU/Day for Autoimmune Disease

At the extreme end of the vitamin D supplementation spectrum sits the Coimbra Protocol, developed by Brazilian neurologist Cicero Coimbra at the Federal University of São Paulo. Coimbra proposes that patients with autoimmune diseases (multiple sclerosis, psoriasis, rheumatoid arthritis, lupus, Hashimoto's thyroiditis, Crohn's disease, and others) have genetic resistance to vitamin D signaling that requires supraphysiologic doses to overcome. His protocol prescribes 40,000–100,000 IU/day of vitamin D3 — 67–167 times the IOM's tolerable upper intake level of 4,000 IU/day — alongside a strict protocol of calcium restriction (low-dairy, low-calcium diet), high fluid intake (2.5 liters/day), and aerobic exercise to prevent hypercalcemia and kidney stones.

The Coimbra Protocol has attracted a large international following of autoimmune disease patients, particularly those with multiple sclerosis and psoriasis who have not achieved satisfactory outcomes with conventional treatments. The Facebook group for Coimbra Protocol patients has over 30,000 members. There are Coimbra-trained physicians across Brazil, Europe, and Latin America. Patient testimonials and before-and-after photo documentation, particularly for psoriasis (a visually dramatic condition), have driven substantial organic growth through social media. The community is tightly organized around Coimbra's framework and resistant to criticism from outside it — a pattern common in communities where patients have found relief from conditions that conventional medicine has treated inadequately.

The safety protocol bundled with the Coimbra doses is itself informative. Hypercalcemia — excess calcium in the blood — is the primary risk of vitamin D toxicity at high doses. Vitamin D increases calcium absorption from the gut; at 40,000–100,000 IU/day, this effect is severe enough to produce kidney stones and soft-tissue calcification without active countermeasures. The Coimbra protocol's calcium restriction, high hydration, and regular monitoring (parathyroid hormone, urinary calcium, kidney function) are attempts to manage this toxicity risk. That the protocol requires these countermeasures to be safe is direct evidence that the doses involved are in the pharmacological toxicity range, not in any "optimal physiological" range. The protocol is not managing a deficiency; it is applying pharmacological doses as therapy while managing their toxicity.

K2 (MK-7) as Mandatory Cofactor: The Belief vs. The Evidence

The combination of vitamin D3 with vitamin K2 (specifically the MK-7 form, menaquinone-7) has become near-universal practice in the vitamin D supplementation community. The K2 cofactor belief rests on a mechanistically plausible hypothesis: vitamin D increases calcium absorption; vitamin K2 activates matrix Gla protein (MGP) and osteocalcin, which are involved in directing calcium to bones rather than arteries; therefore, high-dose vitamin D without K2 could cause arterial calcification even while nominally improving bone density. The "calcium routing" hypothesis is regularly cited in community discussions and has generated a substantial co-supplementation market — D3+K2 combination supplements are among the fastest-growing categories in the vitamin D market.

The mechanistic plausibility is real. Vitamin K-dependent proteins are genuinely involved in calcium metabolism, and observational data show associations between low vitamin K status and arterial calcification. However, the clinical evidence that supplemental K2 combined with vitamin D3 produces better outcomes than vitamin D3 alone is limited. There are no large randomized trials demonstrating that D3+K2 produces meaningfully different cardiovascular or bone outcomes than D3 alone in humans at typical supplementation doses. The trials that exist are small, short-term, and focused on biomarker outcomes (undercarboxylated osteocalcin, MGP) rather than clinical endpoints. The community consensus that K2 is "mandatory" when taking vitamin D3 is based on mechanistic reasoning and limited observational data — it is plausible, it is not proven.

COVID-19 and the Deficiency Narrative's Viral Moment

The COVID-19 pandemic produced a dramatic acceleration in vitamin D supplementation, driven by a legitimate observational finding that metastasized into claims the evidence could not support. Multiple early COVID studies found that patients with severe COVID-19 had lower 25(OH)D levels than patients with mild disease. This association was real and was replicated across multiple studies in multiple countries. It became widely interpreted — in media reporting, in the supplement community, and by some clinicians — as evidence that vitamin D deficiency was a risk factor for severe COVID and that supplementation would reduce severity or prevent infection.

The observational association between low vitamin D and severe COVID is consistent with Autier's reverse causation hypothesis: COVID-19 is an inflammatory disease, and acute severe inflammation reduces 25(OH)D levels. People who became severely ill had lower vitamin D not because low vitamin D caused them to become severely ill, but because severe COVID causes low vitamin D. The prospective studies that might distinguish causation from reverse causation — measuring vitamin D before COVID exposure and following people forward — are difficult to conduct during a pandemic. Several trials of vitamin D supplementation in COVID patients were conducted, with mixed results; meta-analyses of these trials do not show consistent significant benefit for severe outcomes. The UK's CORONAVIT trial (n=6,200, two doses tested) found no significant effect on COVID severity.

The COVID moment is instructive about how vitamin D community dynamics work. A legitimate observational finding — low vitamin D correlates with severe COVID — was amplified far beyond what the evidence warranted by a pre-existing community infrastructure ready to receive it. The supplement market responded within months; vitamin D sales in the US approximately doubled in 2020. The amplification happened through a combination of community forums, YouTube channels, and press coverage that was epistemologically undisciplined. By the time well-designed trials returned null or weak results, the supplementation behavior change was locked in for many people who associated their COVID period supplementation with not getting severely ill — a natural but misleading inference in a pandemic where the vast majority of people, regardless of vitamin D status, had mild or no symptoms.

The VITAL Trial's Negative Primary Outcomes Are Not a Caveat

The most important fact about vitamin D supplementation evidence is that the largest, most rigorous, best-powered randomized trial ever conducted returned negative primary outcomes. VITAL enrolled 25,871 participants, ran for 5.3 years, and was specifically designed to detect a 15% reduction in cancer incidence — a meaningful and clinically significant effect size. It found hazard ratios of 0.96 for cancer incidence and 0.97 for major cardiovascular events — essentially null results whose confidence intervals exclude even modest benefits. This is not a minor trial that happened to be negative. This is the trial that the field needed, properly powered and properly conducted, and it did not find the effects that decades of observational data predicted.

The supplement industry's response to VITAL illustrates a pattern of motivated reasoning that should be understood as such. Common deflections include: the dose was too low (2,000 IU/day); participants weren't selected for deficiency (mean baseline 25(OH)D was 29.8 ng/mL, above the IOM's adequate threshold); the follow-up was too short (5.3 years); the secondary cancer mortality signal in years 3–5 deserves attention; subgroups with low BMI showed benefit. Each of these points has some merit as a hypothesis about why higher doses, deficient populations, or longer follow-up might show benefit. None of them salvages what VITAL actually demonstrated: that supplementing 25,871 American adults at 2,000 IU/day for 5 years did not reduce cancer incidence or cardiovascular events.

A fair summary of the evidence hierarchy is: observational studies consistently show associations; most intervention trials do not show corresponding benefits; the largest, best-powered intervention trial was negative on its primary endpoints. When a field produces strong observational associations that consistently fail to replicate in intervention trials, the most parsimonious explanation is not "the trials were all underpowered or wrongly designed" — it is that the observational associations were not causal. That is Autier's reverse causation hypothesis, and the trial literature is consistent with it.

The Fracture Prevention Evidence Collapse

Bolland's meta-analyses constitute a substantial revision of what was, for decades, one of the most-cited uses of vitamin D supplementation: fracture prevention. The 2018 meta-analysis covering 81 trials and 53,537 participants found no significant reduction in fractures, falls, or bone mineral density with vitamin D supplementation in community-dwelling adults. The 2014 meta-analysis found similar null results for calcium supplementation with or without vitamin D. These findings were specifically challenged by proponents of vitamin D supplementation, but independent analyses have generally confirmed the direction of the results.

The fracture-prevention case illustrates how a plausible mechanism can sustain a clinical belief long past the point where trial evidence would have rejected it. Vitamin D is involved in calcium absorption; calcium is a major component of bone; therefore vitamin D should help prevent fractures. The mechanism is real. The clinical effect in community-dwelling adults at doses achievable from supplementation has not materialized in large trials. The exceptions — severe deficiency in institutionalized elderly, rickets prevention — are real but represent a much narrower population than the "everyone should supplement for bone health" message that reached mass consumer awareness.

The societal cost of misplaced evidence interpretation is not trivial. The calcium plus vitamin D supplement market in the United States exceeds $1 billion annually. Guidelines from osteoporosis organizations that recommended calcium and vitamin D supplementation for broad populations were based substantially on the observational data and smaller trials that Bolland's work later overturned. Clinicians who followed guidelines were not making errors given what was known; they were applying imperfect evidence in good faith. But the lesson for consumers encountering vitamin D marketing claims is that "decades of clinical recommendation" is not the same as "robust randomized trial evidence," and the two can diverge substantially.

The Coimbra Protocol: Extraordinary Doses, No Controlled Evidence

The Coimbra Protocol presents a distinct evidentiary problem. The protocol does not claim modest benefits from modest supplementation — it claims dramatic, sustained remission of autoimmune diseases at doses of 40,000–100,000 IU/day. If true, this would be among the most important therapeutic discoveries in autoimmunology in decades. The evidence base consists of: published case series from Coimbra's practice, patient testimonials, before-and-after photographs (particularly for psoriasis), and a single pilot study by Coimbra and colleagues published in a journal without the profile of the major autoimmune disease journals.

There are no randomized controlled trials of the Coimbra Protocol. There are no independent replications of the case series by researchers unaffiliated with Coimbra's practice. There are no phase II or phase III trials in any autoimmune condition. For a protocol being administered to tens of thousands of patients at doses 67–167 times the established tolerable upper intake level — doses that require active management to prevent life-threatening hypercalcemia — the absence of controlled trial evidence is not a minor gap to be filled eventually; it is a fundamental failure of the standard of evidence expected before widespread clinical adoption.

The vitamin D receptor resistance hypothesis that underlies the Coimbra Protocol — that autoimmune patients have genetic variants that reduce VDR responsiveness, requiring supraphysiologic doses to achieve normal signaling — is speculative. The genetic evidence does not clearly support a uniform VDR resistance phenotype in autoimmune populations. Some VDR polymorphisms (Bsm1, Taq1, Fok1, Apa1) have been associated with autoimmune disease risk in some studies, but the association is inconsistent across populations and disease categories, and none of the identified variants would predict the degree of resistance that the Coimbra dosing scheme implies. The resistance hypothesis was developed to justify the dosing, not derived independently and then applied to dosing decisions.

Toxicity Thresholds: Where the Evidence Actually Runs Out

Vitamin D toxicity (hypervitaminosis D) is definitively established and operates through hypercalcemia — vitamin D elevates calcium absorption, and at supraphysiologic doses, serum calcium rises to levels that cause kidney stones, soft tissue calcification, confusion, cardiac arrhythmias, and kidney failure. The IOM set the tolerable upper intake level at 4,000 IU/day based on the evidence that adverse effects, particularly hypercalcemia, are consistently absent below this level in most adults. The 10,000 IU/day figure is sometimes cited as a "safe upper limit" based on Hathcock et al.'s risk assessment, which argued that no observed adverse effects were documented below this level in most studies.

The 10,000 IU/day threshold is frequently cited in the supplement community as validation that standard high-dose supplementation (5,000–10,000 IU/day) is safe. Several important qualifications apply. Individual sensitivity varies substantially — cases of hypercalcemia have been documented at doses below 10,000 IU/day in individuals with granulomatous diseases (sarcoidosis, tuberculosis), where activated macrophages produce calcitriol independently of the normal regulatory feedback. Primary hyperparathyroidism increases calcium sensitivity. The risk assessment framework assumed typical baseline vitamin D levels, not the already-elevated levels that occur in people who have been supplementing long-term. Long-term safety data at doses of 5,000–10,000 IU/day extending beyond a few years is sparse in the RCT literature; most trials were not designed to assess rare toxicity events over long periods.

The Deficiency Threshold and the "Pandemic of Deficiency" Narrative

The "pandemic of vitamin D deficiency" narrative — the claim that most of the modern population is deficient — depends critically on which 25(OH)D threshold is used to define deficiency. At the IOM's threshold of 20 ng/mL, approximately 25–30% of Americans have levels below adequate. At the Endocrine Society's "insufficiency" threshold of 30 ng/mL, approximately 40–50% fall short. At the community consensus target of 40–60 ng/mL, the majority of Americans supplementing at standard doses would qualify as insufficient. At the aggressive community target of 60–80 ng/mL, virtually everyone not supplementing substantially is "deficient."

The commercial logic here is straightforward: higher thresholds mean larger markets. The Endocrine Society's 30 ng/mL threshold classifies roughly twice as many people as "insufficient" compared to the IOM's 20 ng/mL threshold. Neither threshold is derived directly from randomized trial evidence showing that achieving higher levels produces better outcomes — both are based on observational associations and expert interpretation of mechanistic data, subject to all the limitations Autier identified. The iterative upward creep in community consensus targets — 30 ng/mL was once aspirational, 40 is now common, 60–80 is increasingly recommended in optimization discussions — is a social phenomenon in a community where higher numbers feel like more progress, not a clinical evidence development.

What the Evidence Does and Doesn't Support

A defensible evidence-based summary of vitamin D supplementation as of 2026: correction of genuine, documented deficiency (25(OH)D below 20 ng/mL) in populations with limited sun exposure (elderly institutionalized adults, people with malabsorption disorders, exclusively breastfed infants in northern latitudes, pregnant women with limited sun exposure) has a plausible mechanism and is supported by enough evidence to be reasonable clinical practice. Prevention of rickets in at-risk infants is well-established. These are the legitimate uses.

For broad-population supplementation in adults without documented deficiency to prevent cancer, cardiovascular disease, fractures, autoimmune disease, or COVID-19 severity: the largest trials at doses achievable from supplementation have not shown significant benefits on pre-specified primary endpoints. The K2 cofactor requirement is mechanistically plausible but clinically unproven. The Coimbra Protocol represents an extraordinary pharmacological intervention being administered without controlled trial evidence to patients who deserve better. The "reverse causation" explanation for the gap between compelling observational associations and disappointing trial results has not been definitively proven, but it is consistent with the pattern of evidence and has not been refuted by the intervention trials conducted so far.

The honest uncertainty position is this: vitamin D does important things in human physiology, severe deficiency causes real disease, and the observational epidemiology showing associations with dozens of conditions is genuinely striking. Whether correcting sub-deficiency levels in supplemented Western adults produces meaningful health benefits is not established, and the largest, best-powered trials suggest it does not. Holding both of these positions simultaneously — vitamin D matters for real deficiency, megadosing likely does not produce the benefits attributed to it — is not a contradiction. It is what the evidence shows.